#AANAM – Corticosteroids Aid Muscle Mass in BMD and LGMD, Trials Needed

#AANAM – Corticosteroids Aid Muscle Mass in BMD and LGMD, Trials Needed
5
(3)

Editor’s note: The Muscular Dystrophy News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.

Once-weekly corticosteroid treatment was safe and well-tolerated in people with Becker muscular dystrophy (BMD) or limb-girdle muscular dystrophy (LGMD) in a small clinical trial, and early evidence suggests that corticosteroids can improve muscle mass and muscle function in these patients.

These findings warrant further trials to assess corticosteroid’s potential benefits in treating BMD and LGMD, according to its researchers.

Data were presented in the poster, “24-week open label clinical trial to test safety and efficacy of oral weekly prednisone in adults with Becker (BMD) and Limb-Girdle Muscular Dystrophy (LGMD),” at the 2021 American Academy of Neurology annual meeting.

Corticosteroids (sometimes referred to as “steroids”) are a class of medication that decrease inflammation and closely resemble cortisol, a hormone produced by the adrenal glands. Corticosteroid treatment is common for people with Duchenne muscular dystrophy, and it has been shown to improve walking ability and survival.

Researchers at Northwestern University conducted a small, 24-week Phase 2 clinical trial (NCT04054375) to examine the safety and tolerability of once-weekly corticosteroid use in people with BMD or LGMD.

A total of 20 patients completed the trial: one with BMD and 19 with LGMD. Participants ranged from 18 to 63 years old; about two-thirds were male. Six were able to walk.

Patients were given a corticosteroid called prednisone at doses of 0.75 mg/kg or 1 mg/kg depending on body weight, taken after the last meal every Monday for about six months.

Before and after treatment, they underwent a battery of laboratory and imaging tests. For most of these assessments, values did not significantly differ between the trial’s start and end. The researchers highlighted that these findings indicate that treatment did not cause any noteworthy problems in areas such as weight, metabolism, blood pressure, and breathing ability.

Corticosteroid use, however, led to an increase in lean muscle mass, as well as a decrease in levels of creatine kinase, which is a marker of muscle damage.

Among the six patients able to walk, a trend toward a better walking ability was seen.

Corticosteroid treatment was generally safe and well-tolerated. The most common events were increased anxiety on Monday nights and facial acne. No serious adverse events were reported, and no one discontinued treatment due to side effects. All but one of these 20 patients elected to continue taking weekly corticosteroids after finishing the study.

“Additional multicenter randomized clinical trials are needed to better understand how weekly steroids may benefit patients with BMD and LGMD,” the researchers concluded.

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Total Posts: 42
José holds a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.
×
Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Latest Posts
  • corticosteroids and MD
  • AOC-1001 as DM1 therapy
  • pamrevlumab designation
  • Flavocoxid

How useful was this post?

Click on a star to rate it!

Average rating 5 / 5. Vote count: 3

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?